Ortega Corrie, Anderson Lindsey N, Frando Andrew, Sadler Natalie C, Brown Robert W, Smith Richard D, Wright Aaron T, Grundner Christoph
Center for Infectious Disease Research (formerly Seattle Biomedical Research Institute), Seattle, WA 98109, USA.
Biological Sciences Division, Pacific Northwest National Laboratory, Richland, WA 99352, USA.
Cell Chem Biol. 2016 Feb 18;23(2):290-298. doi: 10.1016/j.chembiol.2016.01.003. Epub 2016 Feb 4.
The transition from replication to non-replication underlies much of Mycobacterium tuberculosis (Mtb) pathogenesis, as non- or slowly replicating Mtb are responsible for persistence and poor treatment outcomes. Therapeutic targeting of non-replicating populations is a priority for tuberculosis treatment, but few drug targets in non-replicating Mtb are currently known. Here, we directly measured the activity of the highly diverse and druggable serine hydrolases (SHs) during active replication and non-replication using activity-based proteomics. We predict SH activity for 78 proteins, including 27 proteins with unknown function, and identify 37 SHs that remain active in the absence of replication, providing a set of candidate persistence targets. Non-replication was associated with major shifts in SH activity. These activity changes were largely independent of SH abundance, indicating extensive post-translational regulation of SHs. By probing a large cross-section of druggable Mtb enzyme space during replication and non-replication, we identify new SHs and suggest new persistence targets.
从复制状态转变为非复制状态是结核分枝杆菌(Mtb)发病机制的重要基础,因为非复制或缓慢复制的Mtb会导致疾病持续存在且治疗效果不佳。针对非复制菌群体的治疗靶点是结核病治疗的重点,但目前已知的非复制Mtb中的药物靶点很少。在此,我们使用基于活性的蛋白质组学直接测量了高度多样化且可成药的丝氨酸水解酶(SHs)在活跃复制和非复制过程中的活性。我们预测了78种蛋白质的SH活性,其中包括27种功能未知的蛋白质,并鉴定出37种在无复制情况下仍保持活性的SHs,从而提供了一组候选的持续性靶点。非复制与SH活性的重大变化相关。这些活性变化在很大程度上与SH丰度无关,表明存在对SHs的广泛翻译后调控。通过在复制和非复制过程中探测可成药的Mtb酶空间的很大一部分,我们鉴定出了新的SHs并提出了新的持续性靶点。